REGN241213P747500
- 6.20
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Weekly Buzz: Tech stocks hit high scores on ominous day
Market Mixed on Friday the 13th | Livestock
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Express News | B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Presents New And Updated Data For Odronextamab At ASH Annual Meeting
Kodiak Stock Rallies 32% After Jefferies Upgrades to Buy
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
Stocks With Best Odds of Risk-adjusted Returns Deserve Attention: Goldman Sachs
- Regeneron Announced Novel Combination Of Pozelimab And Cemdisiran Achieved Greater Control Of Intravascular Hemolysis In Patients With Paroxysmal Nocturnal Hemoglobinuria Vs Ravulizumab
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab